Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT)

This article has no abstract
Epistemonikos ID: f96f245524c0ef8fcaa8cc3c1f96270cf98b3bb8
First added on: Feb 05, 2025